Literature DB >> 24638998

Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance.

Philippa Middleton1, Caroline A Crowther.   

Abstract

BACKGROUND: The early postpartum period is an important time in which to identify the risk of diabetes in women with a history of gestational diabetes mellitus (GDM). Oral glucose tolerance and other tests can help guide lifestyle management and monitoring to reduce the future risk of type 2 diabetes mellitus.
OBJECTIVES: To assess whether reminder systems increase the uptake of testing for type 2 diabetes or impaired glucose tolerance in women with a history of GDM. SEARCH
METHODS: We searched MEDLINE and EMBASE (last searched 1 June 2013) and The Cochrane Library (last searched April 2013). SELECTION CRITERIA: We included randomised trials of women who had experienced GDM in the index pregnancy and who were then sent any modality of reminder (or control) to complete a test for type 2 diabetes after giving birth. DATA COLLECTION AND ANALYSIS: Two authors independently screened titles and abstracts for relevance. One author extracted the data, carried out 'Risk of bias' assessments and evaluated the overall study quality according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria; the other author double-checked these procedures. Meta-analysis was not possible as only one study was eligible for inclusion. MAIN
RESULTS: Only one trial with an unclear risk of bias in the majority of domains was included in the study; the overall study quality was judged to be low. This factorial trial of 256 women compared three types of postal reminder strategies (in a total of 213 women) with usual care (no postal reminder, 43 women) and reported on the uptake of four possible types of glucose tests. The three strategies investigated were: reminders sent to both the woman and the physician; reminder sent to the woman only; and reminder sent to the physician only, all issued approximately three months after the woman had given birth.There was low-quality evidence that all three reminder interventions increased uptake of oral glucose tolerance tests compared with usual care (no reminder system): reminders to the woman and the physician (uptake 60% versus 14%): risk ratio 4.23 (95% confidence interval (CI) 1.85 to 9.71); 116 participants); reminder to the woman only (uptake 55% versus 14%): RR 3.87 (95% CI 1.68 to 8.93); 111 participants); reminder to the physician only (uptake 52% versus 14%): RR 3.61 (95% CI 1.50 to 8.71); 66 participants). This represented an increase in uptake from 14% in the no reminder group to 57% across the three reminder groups. There was also an increase in uptake of fasting glucose tests in the reminder group compared with the usual care group: reminders to the woman and the physician versus no reminder (uptake 63% versus 40%): RR 1.57 (95% CI 1.01 to 2.44); reminder to the woman only (uptake 71% versus 40%): RR 1.78 (95% CI 1.16 to 2.73); reminder to the physician only (uptake 68% versus 40%): RR 1.69 (95% CI 1.06 to 2.72). Uptake of random glucose and glycated haemoglobin A1c tests was low, and no statistically significant differences were seen between the reminder and no reminder groups for these tests. Uptake of any test was higher in each of the reminder groups compared with the no reminder group (RR 1.65 (95% CI 1.12 to 2.41); 1.73 (95% CI 1.18 to 2.52); and 1.55 (95% CI 1.01 to 2.38) in the respective reminder groups.The trial did not report this review's other primary outcomes (proportion of women diagnosed with type 2 diabetes or showing impaired glucose tolerance or impaired fasting glucose after giving birth; or health-related quality of life). Nor did it report any secondary review outcomes such as diabetes-associated morbidity, lifestyle changes, need for insulin, recurrence of GDM or women's and/or health professionals' views of the intervention. No adverse events of the intervention were reported.Subgroup interaction tests gave no indication that dual reminders (to both women and physicians) were more successful than single reminders to either women or physicians alone. It was also not clear if test uptakes between women in the reminder and no reminder groups differed by type of glucose test undertaken. AUTHORS'
CONCLUSIONS: Results from the only trial that fulfilled our inclusion criteria showed low-quality evidence for a marked increase in the uptake of testing for type 2 diabetes in women with previous GDM following the issue of postal reminders. The effects of other forms of reminder systems need to be assessed to see whether test uptake also increases when email and telephone reminders are deployed. We also need a better understanding of why some women fail to take opportunities to be screened postpartum. As the ultimate aim of increasing postpartum testing is to prevent the subsequent development of type 2 diabetes, it is important to determine whether increased test uptake rates also increase women's use of preventive strategies such as lifestyle modifications.

Entities:  

Mesh:

Year:  2014        PMID: 24638998     DOI: 10.1002/14651858.CD009578.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  13 in total

1.  Reciprocal Peer Support for Post-partum Patients with Diabetes: A Needs Assessment for the Diabetes Buddy Program.

Authors:  M Alexandra Friedman; Charlotte M Niznik; Janelle R Bolden; Lynn M Yee
Journal:  J Community Health       Date:  2016-04

Review 2.  Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes.

Authors:  Joanna Tieu; Emily Shepherd; Philippa Middleton; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2017-08-24

3.  Optimizing postpartum care for the patient with gestational diabetes mellitus.

Authors:  Noelle G Martinez; Charlotte M Niznik; Lynn M Yee
Journal:  Am J Obstet Gynecol       Date:  2017-04-26       Impact factor: 8.661

4.  Maternal Race/Ethnicity and Postpartum Diabetes Screening: A Systematic Review and Meta-Analysis.

Authors:  Cynthia J Herrick; Ritika Puri; Rana Rahaman; Angela Hardi; Karyn Stewart; Graham A Colditz
Journal:  J Womens Health (Larchmt)       Date:  2020-02-19       Impact factor: 2.681

5.  An analysis of demographic and pregnancy outcome data to explain non-attendance for postpartum glucose testing in women with gestational diabetes mellitus: Why are patients missing follow-up?

Authors:  Zora A Castling; Tom Farrell
Journal:  Obstet Med       Date:  2018-11-07

Review 6.  Controversies in Gestational Diabetes.

Authors:  Chloe A Zera; Ellen W Seely
Journal:  touchREV Endocrinol       Date:  2021-08-04

Review 7.  The forgotten risk? A systematic review of the effect of reminder systems for postpartum screening for type 2 diabetes in women with previous gestational diabetes.

Authors:  Charlotte Jeppesen; Jette Kolding Kristensen; Per Ovesen; Helle Terkildsen Maindal
Journal:  BMC Res Notes       Date:  2015-08-26

8.  Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women.

Authors:  Girish Rayanagoudar; Amal A Hashi; Javier Zamora; Khalid S Khan; Graham A Hitman; Shakila Thangaratinam
Journal:  Diabetologia       Date:  2016-04-13       Impact factor: 10.122

Review 9.  Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and meta-analysis.

Authors:  Yasmine Ali Abdelhamid; Palash Kar; Mark E Finnis; Liza K Phillips; Mark P Plummer; Jonathan E Shaw; Michael Horowitz; Adam M Deane
Journal:  Crit Care       Date:  2016-09-27       Impact factor: 9.097

Review 10.  Diabetes prevention interventions for women after gestational diabetes mellitus: an overview of reviews.

Authors:  Anne-Mette Hedeager Momsen; Diana Høtoft; Lisbeth Ørtenblad; Finn Friis Lauszus; Rubab Hassan Agha Krogh; Vibeke Lynggaard; Jens Juel Christiansen; Helle Terkildsen Maindal; Claus Vinther Nielsen
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.